Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.

Farkouh ME, Verheugt FW, Ruland S, Kirshner H, Jeger R, Gitton X, Krammer G, Stricker K, Sallstig P, Mellein B, Matchaba P, Chesebro JH.

J Clin Hypertens (Greenwich). 2008 Aug;10(8):592-602.

2.

Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.

MacDonald TM, Reginster JY, Littlejohn TW, Richard D, Lheritier K, Krammer G, Rebuli R.

J Hypertens. 2008 Aug;26(8):1695-702. doi: 10.1097/HJH.0b013e328302c9fe.

PMID:
18622250
3.

Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.

Hawkey CJ, Weinstein WM, Smalley W, Gitton X, Sallstig P, Stricker K, Krammer G, Mellein B, Richard D, Matchaba P.

Gastroenterology. 2007 Jul;133(1):57-64. Epub 2007 Apr 27.

PMID:
17631131
4.

Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.

Bannwarth B, Berenbaum F.

Expert Opin Investig Drugs. 2005 Apr;14(4):521-33. Review.

PMID:
15882125
5.

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.

Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.

Clin Ther. 2005 Aug;27(8):1196-214. Review.

PMID:
16199245
6.

Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial.

Hawkey CJ, Weinstein WM, Stricker K, Murphy V, Richard D, Krammer G, Rebuli R.

Aliment Pharmacol Ther. 2008 May;27(9):838-45. doi: 10.1111/j.1365-2036.2008.03622.x. Epub 2008 Jan 22.

7.

Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.

Hawkey CJ, Farkouh M, Gitton X, Ehrsam E, Huels J, Richardson P.

Aliment Pharmacol Ther. 2004 Jul 1;20(1):51-63.

8.
9.

Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.

Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FW, Chesebro JH, Kirshner H, Hochman JS, Lay CL, Ruland S, Mellein B, Matchaba PT, Fuster V, Abramson SB.

Ann Rheum Dis. 2007 Jun;66(6):764-70. Epub 2007 Apr 5.

10.

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ; TARGET Study Group.

Lancet. 2004 Aug 21-27;364(9435):665-74.

PMID:
15325831
11.

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH; TARGET Study Group.

Lancet. 2004 Aug 21-27;364(9435):675-84.

PMID:
15325832
12.

Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.

Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C.

Aliment Pharmacol Ther. 2004 Jun 1;19(11):1189-98.

13.
14.

Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.

Hawkey CJ, Gitton X, Hoexter G, Richard D, Weinstein WM.

Clin Gastroenterol Hepatol. 2006 Jan;4(1):57-66.

PMID:
16431306
15.

Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis.

White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M.

Am J Cardiol. 2009 Sep 15;104(6):840-5. doi: 10.1016/j.amjcard.2009.05.014.

PMID:
19733721
16.

The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty.

Chan VW, Clark AJ, Davis JC, Wolf RS, Kellstein D, Jayawardene S.

Acta Anaesthesiol Scand. 2005 Nov;49(10):1491-500.

PMID:
16223396
17.

Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.

Daniels S, Gitton X, Zhou W, Stricker K, Barton S.

J Womens Health (Larchmt). 2008 Apr;17(3):423-37. doi: 10.1089/jwh.2007.0416.

PMID:
18373490
18.

Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis.

Geusens P, Alten R, Rovensky J, Sloan VS, Krammer G, Kralidis G, Richardson P.

Int J Clin Pract. 2004 Nov;58(11):1033-41.

PMID:
15605667
19.

Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.

Hawkey CJ, Ell C, Simon B, Albert J, Keuchel M, McAlindon M, Fortun P, Schumann S, Bolten W, Shonde A, Hugot JL, Yu V, Arulmani U, Krammer G, Rebuli R, Toth E.

Clin Gastroenterol Hepatol. 2008 May;6(5):536-44. doi: 10.1016/j.cgh.2007.12.023. Epub 2008 Jan 31.

PMID:
18242145
20.

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.

Fleischmann R, Tannenbaum H, Patel NP, Notter M, Sallstig P, Reginster JY.

BMC Musculoskelet Disord. 2008 Mar 7;9:32. doi: 10.1186/1471-2474-9-32.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk